Abstract
Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Adolescent Psychiatry
Title: The Therapeutic Community for the Adolescent Substance Abuser
Volume: 1 Issue: 2
Author(s): Gregory C. Bunt and Britta Muehlbach
Affiliation:
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Abstract: Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Export Options
About this article
Cite this article as:
C. Bunt Gregory and Muehlbach Britta, The Therapeutic Community for the Adolescent Substance Abuser, Adolescent Psychiatry 2011; 1 (2) . https://dx.doi.org/10.2174/2210676611101020122
DOI https://dx.doi.org/10.2174/2210676611101020122 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer's Disease and Chinese Medicine as a Useful Alternative Intervention Tool: A Mini-Review
Current Alzheimer Research Intracellular Retention of Three Quinuclidine Derivatives in Caco-2 Permeation Experiments: Mechanisms and Impact on Estimating Permeability and Active Efflux Ratio
Drug Metabolism Letters Derivatives of IL-16 to Modulate Airway Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease
Cardiovascular & Hematological Disorders-Drug Targets A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders
Current Neuropharmacology Opioid Dependency and Myocardial Infarction: A Systematic Review and Meta-Analysis
Current Reviews in Clinical and Experimental Pharmacology 1,4-Benzothiazines-A Biologically Attractive Scaffold
Mini-Reviews in Medicinal Chemistry Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Lipid Rafts Mediate Amyloid-Induced Calcium Dyshomeostasis and Oxidative Stress in Alzheimer’s Disease
Current Alzheimer Research Abnormal Striatal Dopamine Transmission in Schizophrenia
Current Medicinal Chemistry The Regulatory Roles of Mitogen-Activated Protein Kinase (MAPK) Pathways in Health and Diabetes: Lessons Learned from the Pancreatic β-Cell
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Zinc Hydrogen Sulfate Promoted Multi-component Preparation of Highly Functionalized Piperidines
Letters in Organic Chemistry Cerebrospinal-fluid Alzheimer’s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Living without Oxygen: Anoxia-Responsive Gene Expression and Regulation
Current Genomics Linking Antimicrobial Potential of Natural Products Derived from Aquatic Organisms and Microbes Involved in Alzheimer’s Disease - A Review
Current Medicinal Chemistry Mesenchymal Stem Cells: Potential in Treatment of Neurodegenerative Diseases
Current Stem Cell Research & Therapy Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Prediction of Cyclin Proteins Using Chou's Pseudo Amino Acid Composition
Protein & Peptide Letters Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design